Global agreement strengthens customized manufacturing solutions for upstream and downstream processing and moves the ‘disposable factory’ closer to reality
The companies will combine their expertise in generating application data on filter and mixing performance with critical purification buffers and cell culture media. Similarly, extractable and leachable data will be generated with buffers and media, and filters and biobag combinations. In addition, SAFC expects to utilize SSB technology for storage and mixing of cell culture media to optimize its fluid/powder handling systems. According to the agreement, each company will offer its products with the assistance and support of its partner, working together to better serve customers in solution creation, validation support, process improvement, technical support and problem solving. Additionally, the strength of the partnership’s combined technical resources should create a larger range of integrated manufacturing solutions and a wider array of options for biopharmaceutical manufacturing customers.
Archie Cullen, SAFC Vice President Global Sales, explained the benefits for SAFC, stating: “Sartorius Stedim Biotech offers SAFC Biosciences the opportunity to partner with a market leader in process and single-use technologies development, and enables us to provide integrated, single-use systems to the global biopharmaceutical cell culture community. This agreement enhances our position as the cell culture partner with the widest range of highly customized products and services. It further demonstrates that our customer intimacy approach helps us lead as the biopharmaceutical industry’s “responsive expert”.
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros. For more information about SSB, visit www.sartorius-stedim.com
About SAFC: SAFC((R)) is the custom manufacturing and services business unit within Sigma-Aldrich that focuses on high-purity inorganics for high technology applications, cell culture products and services for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials. SAFC has four business segments - SAFC Pharma((R)), SAFC Supply Solutions((R)), SAFC Biosciences((R)), and SAFC Hitech((R)) - and had annual sales of over $620 million in 2008. SAFC is considered a top 10 fine chemical company. For more information about SAFC, visit www.safcglobal.com.
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company’s expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies’ operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.
SOURCE Sigma-Aldrich
CONTACT: Bruce Lehr, Director of Marketing of SAFC Biosciences,
+1-913-227-6790, bruce.lehr@sial.com; or media, Mark Button of Impress
Public Relations, +1-503-616-3817, mark@impress-pr.com, for Sigma-Aldrich
Web site: http://www.sigma-aldrich.com/
